Peptides and the regulatory line: why categories and compliance matter
Why distinct compounds sit on different sides of regulatory frameworks, and why conflating them is a costly, risky mistake.
Heredity Editorial · May 25, 2026 · 9 min
Much of the confusion around peptides is really confusion about categories. Different compounds sit on different sides of regulatory frameworks, and treating them as one bucket is a costly mistake.
Compliance is a feature
For a company in this space, compliance is not red tape; it is the product. Clinical oversight, valid prescriptions, and licensed pharmacy fulfillment are what separate a legitimate model from a risky one.
Why Heredity is application-only
Reviewing applications is part of how we stay on the right side of that line. It lets us confirm suitability and maintain accountability, rather than dispensing to anyone who arrives with a card.
How Heredity approaches this
Heredity is application-only and clinically supervised. Membership is reviewed, not sold, and any protocol is designed and overseen by a licensed clinician, then compounded by a licensed U.S. pharmacy partner.
Nothing in this article is medical advice, nor a claim that any peptide diagnoses, treats, cures, or prevents any condition. Suitability is assessed individually. If a topic here is relevant to you, the right next step is a conversation, not a purchase.
Educational information only — not medical advice. Nothing here is intended to diagnose, treat, cure, or prevent any condition. Membership is reviewed individually; any protocol is overseen by a licensed clinician and dispensed by a licensed U.S. pharmacy partner. See our medical disclaimer.
